help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Imseis, R. E.
Right arrow Articles by Vanmiddlesworth, N. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Imseis, R. E.
Right arrow Articles by Vanmiddlesworth, N. R.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 2 685-687
Copyright © 1998 by The Endocrine Society


Original Studies

Pretreatment with Propylthiouracil But Not Methimazole Reduces the Therapeutic Efficacy of Iodine-131 in Hyperthyroidism

Raed E. Imseis, L. Vanmiddlesworth, James D. Massie, Andrew J. Bush and N. R. Vanmiddlesworth

Department of Medicine, Division of Endocrinology (R.E.I., L.V.), Department of Radiology (J.D.M.), Department of Preventive Medicine (A.J.B.), Department of Physiology and Biophysics (L.V., N.R.V.), University of Tennessee, Memphis, Tennessee 38163

Address all correspondence and requests for reprints to: L. Vanmiddlesworth, Ph.D., M.D., University of Tennessee, 894 Union Avenue, Memphis, Tennessee 38163. E-mail: lvanmid{at}physio1.utmem.edu

Ninety-three hyperthyroid patients were treated with 1 dose of iodine-131 (131I) during the past 10 years. Thirty-three were pretreated with propylthiouracil (PTU), 22 with methimazole (MMI), and 38 received no antithyroid drugs (ATD). ATD were discontinued 5–55 days before 131I therapy in three fourths of the cases and more than 4 months before therapy in one fourth of the cases. The frequency of cures in the 3 groups, 6–8 months after radioiodine therapy, was retrospectively studied. The cure rate among those who discontinued PTU for 5–55 days before 131I was significantly reduced (24%), compared with those who discontinued MMI for the same duration (61%) or those who received no ATD (66%). When PTU was discontinued for more than 4 months, the cure rate was similar to those who received no ATD.

It is concluded that if ATD are used as initial therapy for hyperthyroidism, then PTU (but not MMI) may reduce the therapeutic efficacy of subsequent 131I. The reduction in cure rate was observed even when PTU was discontinued for as long as 55 days before 131I therapy.

To our knowledge, this is the first report to compare, in one study, the effects of pretreatment with PTU and MMI on 131I therapy.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society